Literature DB >> 1656873

Activity of new quinolones against ciprofloxacin-resistant staphylococci.

G J Forstall1, C C Knapp, J A Washington.   

Abstract

Because of the development of newer fluoroquinolones with improved activity against gram-positive organisms, we elected to compare the inhibitory properties of ofloxacin, temafloxacin, sparfloxacin, PD131628, PD127391, and WIN57273 against 105 ciprofloxacin-resistant staphylococci. Based on comparison of MICs for 90% of the organisms (MIC90s), WIN57273 was the most active agent against oxacillin-resistant Staphylococcus aureus; the MIC90 was 0.5 microgram/ml. Against oxacillin-resistant, coagulase-negative staphylococci, PD127391 and WIN57273 were the most active agents; the MIC90 was 0.5 microgram/ml. Against isolates of staphylococci for which ciprofloxacin MICs were greater than or equal to 32 micrograms/ml, WIN57273 and PD127391 still exhibited high activity, inhibiting 100 and 95% of the isolates, respectively, at 2 micrograms/ml. The spontaneous mutation rates for ciprofloxacin-susceptible staphylococci were lowest for ofloxacin. The frequency of spontaneous mutations of ciprofloxacin-resistant staphylococci was low; however, the MICs of PD127391 and WIN57273 for these mutant isolates were greater than 2 micrograms/ml. WIN57273 and PD127391 are two potent new quinolones with high levels of activity against highly ciprofloxacin-resistant staphylococci. There is, however, a major concern of selection of spontaneous mutants resistant to these newer agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656873      PMCID: PMC245243          DOI: 10.1128/AAC.35.8.1679

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.

Authors:  M C Raviglione; J F Boyle; P Mariuz; A Pablos-Mendez; H Cortes; A Merlo
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent.

Authors:  G M Eliopoulos; K Klimm; L B Rice; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci.

Authors:  M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

4.  In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent.

Authors:  M A Cohen; M D Huband; G B Mailloux; S L Yoder; G E Roland; J M Domagala; C L Heifetz
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

5.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

6.  The in-vitro activity of PD127,391, a new quinolone.

Authors:  A King; C Boothman; I Phillips
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

7.  Increasing resistance of Staphylococcus aureus to ciprofloxacin.

Authors:  T E Daum; D R Schaberg; M S Terpenning; W S Sottile; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

8.  Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.

Authors:  A Z Chaudhry; C C Knapp; J Sierra-Madero; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

9.  Activity of ciprofloxacin against resistant clinical isolates.

Authors:  S G Kelley; M A Bertram; L S Young
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

10.  In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.

Authors:  A L Barry; R N Jones
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

View more
  13 in total

Review 1.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  New quinolones and gram-positive bacteria.

Authors:  L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

3.  In vitro antimicrobial susceptibilities of Nocardia species.

Authors:  N Khardori; R Shawar; R Gupta; B Rosenbaum; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

4.  Examination of methicillin-resistant and methicillin-susceptible Staphylococcus aureus mutants with low-level fluoroquinolone resistance.

Authors:  M C Sulavik; N L Barg
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

5.  Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection.

Authors:  D S Kernodle; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

6.  CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; K C Lamp; E M Bailey; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

7.  In vitro antistaphylococcal activities of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with those of ciprofloxacin, mupirocin (pseudomonic acid), and peptide-class antimicrobial agents.

Authors:  K E Aldridge
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

8.  Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.

Authors:  A G Miranda; A R Wanger; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 9.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

10.  In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.

Authors:  N Khardori; H Nguyen; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.